JPWO2020069184A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020069184A5
JPWO2020069184A5 JP2021516997A JP2021516997A JPWO2020069184A5 JP WO2020069184 A5 JPWO2020069184 A5 JP WO2020069184A5 JP 2021516997 A JP2021516997 A JP 2021516997A JP 2021516997 A JP2021516997 A JP 2021516997A JP WO2020069184 A5 JPWO2020069184 A5 JP WO2020069184A5
Authority
JP
Japan
Prior art keywords
cancer
domain
use according
antigen
binding domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021516997A
Other languages
Japanese (ja)
Other versions
JP2022502043A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053240 external-priority patent/WO2020069184A2/en
Publication of JP2022502043A publication Critical patent/JP2022502043A/en
Publication of JPWO2020069184A5 publication Critical patent/JPWO2020069184A5/ja
Pending legal-status Critical Current

Links

Claims (14)

それを必要とするヒト対象におけるがんを処置するための医薬組成物を製造するための自家Ｔ細胞集団の使用であって、ここにおいて前記自家Ｔ細胞が、ＣＤ１９／ＣＤ２２抗原結合性ドメインを含む細胞外抗原結合性ドメイン、膜貫通ドメイン、および細胞内シグナル伝達ドメインを含むＣＤ１９／ＣＤ２２タンデムキメラ抗原受容体（ＣＡＲ）をコードする核酸配列を含み、前記ＣＤ１９／ＣＤ２２タンデムＣＡＲが、配列番号２、４、６１、６３、６５、６７、６９、７１、７３、７５、７７、７９、８１、または８３を含むアミノ酸配列を含み、それによりヒト対象のがんを処置する、使用。Use of an autologous T cell population to manufacture a pharmaceutical composition for treating cancer in a human subject in need thereof, wherein said autologous T cells comprise a CD19/CD22 antigen binding domain a nucleic acid sequence encoding a CD19/CD22 tandem chimeric antigen receptor (CAR) comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular signaling domain, wherein said CD19/CD22 tandem CAR comprises SEQ ID NO: 2; A use comprising an amino acid sequence comprising 4, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, or 83, thereby treating cancer in a human subject. 前記膜貫通ドメインが、Ｔ細胞受容体のアルファ、ベータもしくはゼータ鎖、ＣＤ８、ＣＤ２８、ＣＤ３イプシロン、ＣＤ４５、ＣＤ４、ＣＤ５、ＣＤ９、ＣＤ１６、ＣＤ２２、ＣＤ３３、ＣＤ３７、ＣＤ６４、ＣＤ８０、ＣＤ８６、ＣＤ１３４、ＣＤ１３７、およびＣＤ１５４の膜貫通ドメインを含む、請求項１に記載の使用。said transmembrane domain is a T cell receptor alpha, beta or zeta chain, CD8, CD28, CD3 epsilon, CD45, CD4, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 , and the transmembrane domain of CD154. 前記細胞外抗原結合性ドメインが、ＣＤ１９／ＣＤ２２抗原結合性ドメイン、細胞内シグナル伝達ドメインを含み、ＣＤ１９／ＣＤ２２抗原結合性ドメイン、細胞内シグナル伝達ドメイン、またはその両方がリンカーまたはスペーサードメインによって膜貫通ドメインに接続されている、請求項１に記載の使用。The extracellular antigen-binding domain comprises a CD19/CD22 antigen-binding domain, an intracellular signaling domain, wherein the CD19/CD22 antigen-binding domain, the intracellular signaling domain, or both are transmembrane-spanned by a linker or spacer domain. Use according to claim 1, connected to a domain. 前記リンカーまたはスペーサードメインが、ＣＤ８またはＣＤ２８の細胞外ドメインに由来し、膜貫通ドメイン連結されている、請求項３に記載の使用。4. Use according to claim 3, wherein the linker or spacer domain is derived from the extracellular domain of CD8 or CD28 and is transmembrane domain linked. 前記細胞外抗原結合性ドメインが、ＣＤ１９／ＣＤ２２抗原結合性ドメインを含み、ＣＤ１９／ＣＤ２２抗原結合性ドメインに、リーダーペプチドをコードするリーダーヌクレオチド配列が先行する、請求項１に記載の使用。2. Use according to claim 1, wherein said extracellular antigen-binding domain comprises a CD19/CD22 antigen-binding domain, the CD19/CD22 antigen-binding domain being preceded by a leader nucleotide sequence encoding a leader peptide. 前記細胞内シグナル伝達ドメインが、ＯＸ４０、ＣＤ７０、ＣＤ２７、ＣＤ２８、ＣＤ５、ＩＣＡＭ－１、ＬＦＡ－１（ＣＤ１１ａ／ＣＤ１８）、ＩＣＯＳ（ＣＤ２７８）、ＤＡＰ１０、ＤＡＰ１２、４－１ＢＢ（ＣＤ１３７）およびそれらの組み合わせからなる群から選択されたタンパク質の機能的シグナル伝達ドメインを含む共刺激ドメインを含む、請求項１に記載の使用。wherein said intracellular signaling domain is OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, 4-1BB (CD137) and combinations thereof 2. Use according to claim 1, comprising a co-stimulatory domain comprising a functional signaling domain of a protein selected from the group consisting of: 前記ＣＤ１９／ＣＤ２２タンデムキメラ抗原受容体（ＣＡＲ）をコードする前記核酸配列が、配列番号１、３、６０、６２、６４、６６、６８、７０、７２、７４、７６、７８、８０、もしくは８２を含むヌクレオチド配列、または８５％の同一性を有するその配列によってコードされる、請求項１に記載の使用。wherein said nucleic acid sequence encoding said CD19/CD22 tandem chimeric antigen receptor (CAR) is SEQ ID NO: 1, 3, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, or 82 or encoded by a sequence thereof with 85% identity. 前記細胞内シグナル伝達ドメインが、共刺激ドメイン、一次シグナル伝達ドメイン、またはそれらの任意の組合せを含む、請求項１に記載の使用。2. Use according to claim 1, wherein said intracellular signaling domain comprises a co-stimulatory domain, a primary signaling domain, or any combination thereof. 前記細胞内シグナル伝達ドメインが、ＣＤ３ゼータ細胞内ドメインを含む、請求項１に記載の使用。2. Use according to claim 1, wherein said intracellular signaling domain comprises a CD3 zeta intracellular domain. 前記がんが血液学的がんである、請求項１に記載の使用。Use according to claim 1, wherein said cancer is hematological cancer. 前記血液学的がんが、白血病またはリンパ腫である、請求項１０に記載の使用。11. Use according to claim 10, wherein said hematologic cancer is leukemia or lymphoma. 前記白血病が、慢性リンパ性白血病（ＣＬＬ）、急性リンパ性白血病（ＡＬＬ）または慢性骨髄性白血病（ＣＭＬ）である、請求項１１に記載の使用。12. Use according to claim 11, wherein said leukemia is chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL) or chronic myelogenous leukemia (CML). 前記リンパ腫が、マントル細胞リンパ腫、非ホジキンリンパ腫またはホジキンリンパ腫である、請求項１１に記載の使用。12. Use according to claim 11, wherein said lymphoma is mantle cell lymphoma, non-Hodgkin's lymphoma or Hodgkin's lymphoma. 前記がんが、口腔および咽頭がん、消化器系がん、呼吸器系がん、骨および関節のがん、軟組織がん、皮膚がん、中枢神経系の腫瘍、乳がん、生殖系がん、泌尿器系がん、眼および眼窩のがん、内分泌系がん、ならびに脳がんからなる群から選択された成人癌である、請求項１に記載の使用。said cancer is oral and pharyngeal cancer, gastrointestinal cancer, respiratory cancer, bone and joint cancer, soft tissue cancer, skin cancer, central nervous system tumor, breast cancer, reproductive cancer , cancer of the urinary system, cancer of the eye and orbit, cancer of the endocrine system, and cancer of the brain.
JP2021516997A 2018-09-26 2019-09-26 Compositions and Methods for Treating Cancer with Anti-CD19 / CD22 Immunotherapy Pending JP2022502043A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736955P 2018-09-26 2018-09-26
US62/736,955 2018-09-26
PCT/US2019/053240 WO2020069184A2 (en) 2018-09-26 2019-09-26 Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy

Publications (2)

Publication Number Publication Date
JP2022502043A JP2022502043A (en) 2022-01-11
JPWO2020069184A5 true JPWO2020069184A5 (en) 2022-09-30

Family

ID=68343436

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021516997A Pending JP2022502043A (en) 2018-09-26 2019-09-26 Compositions and Methods for Treating Cancer with Anti-CD19 / CD22 Immunotherapy

Country Status (7)

Country Link
US (2) US10822412B2 (en)
EP (1) EP3856235A2 (en)
JP (1) JP2022502043A (en)
CN (1) CN113286607A (en)
AU (1) AU2019350865A1 (en)
CA (1) CA3114349A1 (en)
WO (1) WO2020069184A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200005655A (en) 2017-05-15 2020-01-15 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Non-cistronic Chimeric Antigen Receptors and Uses thereof
CA3078962A1 (en) * 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
US11242389B2 (en) * 2018-09-26 2022-02-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
US11497770B2 (en) 2020-06-22 2022-11-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
US20230399627A1 (en) * 2020-11-02 2023-12-14 Sph Biotherapeutics (Shanghai) Limited. Vector genetically engineered with chimeric antigen receptor and against two or more targets and application thereof
CA3171093A1 (en) * 2020-11-05 2022-05-12 Dina SCHNEIDER Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
KR102393776B1 (en) * 2020-12-30 2022-05-04 (주)이노베이션바이오 Humanized antibody specific for CD22 and chimeric antigen receptor using the same
US20240082402A1 (en) * 2021-01-22 2024-03-14 Elpis Biopharmaceuticals Bispecific chimeric antigen receptors binding to cd19 and cd22
CN113527518A (en) * 2021-07-19 2021-10-22 广州百暨基因科技有限公司 Bispecific chimeric antigen receptor targeting CD22 and CD19 and application thereof
KR20230072536A (en) * 2021-11-17 2023-05-25 (주)이노베이션바이오 Humanized antibody specific for CD22 and chimeric antigen receptor using the same
WO2023129937A1 (en) * 2021-12-29 2023-07-06 Century Therapeutics, Inc. Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof
CN114478803B (en) * 2022-02-11 2023-09-26 北京大学深圳研究生院 Construction and application of novel bispecific chimeric antigen receptor
US20240123068A1 (en) * 2022-10-18 2024-04-18 Kite Pharma, Inc. Cd19 binders, car-t constructs comprising the same, and methods of using the same
CN116462770B (en) * 2023-04-18 2024-03-08 科弈(浙江)药业科技有限公司 Humanized antibody of CD19, CAR-T cell expressing bispecific chimeric antigen receptor and application thereof

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060165A (en) 1962-10-23 Preparation of toxic ricin
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4486414A (en) 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5208021A (en) 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
FI102355B (en) 1988-02-11 1998-11-30 Squibb Bristol Myers Co A method for preparing anthracycline immunoconjugates having a linking spacer
US5076973A (en) 1988-10-24 1991-12-31 Arizona Board Of Regents Synthesis of dolastatin 3
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5138036A (en) 1989-11-13 1992-08-11 Arizona Board Of Regents Acting On Behalf Of Arizona State University Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JP3266311B2 (en) 1991-05-02 2002-03-18 生化学工業株式会社 Novel polypeptide and anti-HIV agent using the same
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
AU668384B2 (en) 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE234635T1 (en) 1995-12-22 2003-04-15 Bristol Myers Squibb Co COUPLERS CONTAINING BRANCHED HYDRAZONE GROUPS
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
CN107213469A (en) 2003-11-06 2017-09-29 西雅图基因公司 Monomethyl valine compound that can be with ligand coupling
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
JP2013505944A (en) 2009-09-24 2013-02-21 シアトル ジェネティックス， インコーポレイテッド DR5 ligand drug conjugate
WO2011106723A2 (en) 2010-02-26 2011-09-01 Lpath, Inc. Anti-paf antibodies
US10738116B2 (en) * 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
CN114958764A (en) * 2015-04-08 2022-08-30 诺华股份有限公司 CD20 therapy, CD22 therapy, and combination therapy with CD19 Chimeric Antigen Receptor (CAR) -expressing cells
EP4282969A3 (en) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars

Similar Documents

Publication Publication Date Title
JP2020533958A5 (en)
JP2020513829A5 (en)
JP2022113880A5 (en)
US20220332790A1 (en) Trifunctional t cell-antigen coupler and methods and uses thereof
JPWO2020069184A5 (en)
JP2020517295A5 (en)
JP2020114264A5 (en)
JP2018535701A5 (en)
JPWO2021102337A5 (en)
JP2019534246A5 (en)
RU2020100865A (en) TREATMENT OF CANCER USING A HUMANIZED ANTI-CD19 CHIMERIC ANTIGENIC RECEPTOR
JP2021177771A5 (en)
JP2021500881A5 (en)
JP2023139070A5 (en)
KR20180002604A (en) Chimeric antigen receptor (CAR) targeting compositions of hematological malignancies, compositions and uses thereof
JP2018515123A5 (en)
KR20200130395A (en) Dimer antigen receptor (DAR)
JP2004529636A5 (en)
JP2021502070A5 (en)
CA3189677A1 (en) Chimeric molecules providing targeted costimulation for adoptive cell therapy
JPWO2020061498A5 (en)
JP2023500338A (en) CAR-T cell therapy targeting BCMA for multiple myeloma
JPWO2020181164A5 (en)
JPWO2020228825A5 (en)
JPWO2020113108A5 (en)